Cardiff Oncology Director Receives 40K Stock Options at $3.16 Strike Price
Cardiff Oncology director James O. Armitage received a new stock option grant on June 26, 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Cardiff Oncology director James O. Armitage received a new stock option grant on June 26, 2025. The derivative securities transaction details include:
- Granted 40,565 stock options to purchase common stock
- Exercise price set at $3.16 per share
- Options become exercisable on June 26, 2026
- Options expire on June 26, 2035
- Following this grant, Armitage now beneficially owns 187,539 derivative securities directly
This Form 4 filing represents a standard director compensation stock option grant, which vests one year from the grant date and has a 10-year exercise period. The transaction appears to be part of the company's regular director compensation program rather than an open market transaction.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Options | 40,565 | $0.00 | $0.00 |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many stock options did CRDF director James Armitage receive on June 26, 2025?
What is the expiration date for James Armitage's new CRDF stock options?
How many total stock options does James Armitage own in CRDF after this grant?
What is the exercise price of CRDF stock options granted to James Armitage in June 2025?
When do James Armitage's new CRDF stock options become exercisable?
AI-generated analysis. How Rhea-AI works. Not financial advice.